ClinicalTrials.gg
WithdrawnNCT01440361Updated Jul 28, 2014

A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.

A Phase 2 interventional study of Belimumab and Normal saline placebo in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-07-28.

Sponsored by GlaxoSmithKline · Phase 2 and Interventional

Why this study was withdrawn
This study was Cancelled Before Active

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Purpura by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Purpura · GlaxoSmithKline.

Enrollment
10th of 10
0 · median 53
Started
2013
the only one that year
Phase 2
4 of 12
none open now
Registered
12th of 12
by date

Among the 12 studies in Purpura by GlaxoSmithKline, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 2, and was the 12th registered.

Purpura

45 studies on the registry are indexed under Purpura; 4 are open to participants now.

Browse Purpura studies →

Open to participants now

None of the 12 studies in Purpura by GlaxoSmithKline is open now. The open studies under Purpura, anywhere →

Who these studies take

Of the 4 Purpura studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Purpura by GlaxoSmithKline as a file.
02

Study summary

Chronic immune thrombocytopenia (ITP) is a longterm disease in which the blood does not clot normally. This is due to a low number of blood cell fragments called platelets. Platelets clot to seal small cuts or breaks on blood vessel walls and stop bleeding. Normally the immune system makes proteins called antibodies to fight off harmful substances that enter the body. In ITP, the immune system produces antibodies that attack and destroy the body's platelets by mistake.

Patients can suffer from bleeding under the skin, nosebleeds, blood in urine or stools and in very severe cases bleeding in the brain. Patients have an increased frequency of death from bleeding complications compared to normal.

Chronic ITP is fairly rare , with an incidence of 32 new cases/million people each year.

Existing treatments work by lowering the activity of the immune system or directly increasing platelet count. These treatments do not work effectively in all patients and can have side effects. We hope that understanding how belimumab works in ITP will help in the development of future treatments for ITP and other autoimmune diseases.

We will test the safety, blood levels and effects of the study medication in people with chronic ITP. Patients will receive the study medication intravenously (through a needle inserted into a vein) and blood samples will be taken before and on several occasions afterwards.

Up to 40 patients with chronic ITP, aged 18 to 75 will participate. Approximately 11 patients will take dummy medicine instead of the study medicine neither they or their study doctor will know which one they are given. Participants will take up to 57 weeks to finish the study. They'll make 12 outpatient visits.

The study will take place in hospitals in the UK. Other sites in mainland Europe may also be initiated.

A pharmaceutical company, GlaxoSmithKline, is funding the study.

03

Conditions studied

  • Purpura, Thrombocytopaenic, Idiopathic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female,18-75 years old
  • Chronic ITP for a minimum of 6 months with a count \<75,000/uL at screening and a platelet count \<75,000/uL 2 to 6 months before screening
  • Stable either on no treatment or on a stable dose of (10 milligrams(mg)/day prednisone or prednisone equivalent or less) and/or azathioprine (100mg/day or less) for a minimum of 30 days before screening
  • Single \<450 milliseconds (msec); or QTc \<480 msec in subjects with Bundle Branch Block
  • A female subject is eligible to participate if she is not pregnant or nursing and at least one of the following conditions apply: a. Non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea. b.Child-bearing potential and agrees to use one of the methods listed in the protocol

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of ITP is secondary to other conditions
  • Treated with any B cell targeted therapy at any time
  • Have received any of the following within 364 days prior to Day 0: Abatacept, A biologic agent other than B cell targeted therapy
  • Have received any of the following within 180 days prior to Day 0: Intravenous (IV) cyclophosphamide, 3 or more courses of systemic for concomitant conditions
  • Have received any of the following within 90 days prior to Day 0: High dose corticosteroid for treatment of ITP, Splenectomy, plasmapheresis
  • Have received any of the following within 60 days, 5 half-lives or twice the duration of the biological effect of belimumab before Day 0: A non-biologic investigational agent, any other /immunomodulatory agent with the exception of azathioprine and corticosteroids, Eltrombopag, romiplostim, any steroid injection
  • Have received any of the following within 30 days before Screening: Intravenous immunoglobulin, Corticosteroids greater than 10mg/day (prednisone or prednisone equivalent) or azathioprine more than 100 mg/day, Changes to corticosteroid or azathioprine therapy
  • Have received a within 30 days before Day 0
  • Subject could be at risk of haemorrhage that threatens a vital organ
  • History of a major organ transplant or hematopoietic stem cell/marrow transplant
  • History of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix
  • Required management of infections, as follows: Currently on any suppressive therapy for a chronic infection, Hospitalisation for treatment of infection within 60 days before Day 0, Use of parenteral antibiotics within 60 days before Day 0
  • Significant unstable or uncontrolled acute or chronic diseases not due to ITP or planned surgical procedure or a history of any other medical disease, laboratory abnormality, or condition that makes the subject unsuitable for the study
  • Positive screening antibody result or (HB) infection
  • Positive test for (HIV) antibody at screening or historically
  • (AST) and alanine aminotransferase (ALT) greater or equal to 2x (ULN); alkaline phosphatase and >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%)
  • IgA deficiency (IgA \<10mg/dL)
  • Abnormal lab results
  • Lymphocyte count \<500/mm3
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy including a previous anaphylactic reaction to parenteral administration contrast agents, human or murine proteins or monoclonal antibodies
  • Evidence of serious suicide risk
  • Current drug or alcohol abuse or dependence
  • Where participation in the study would result in donation of blood or blood products >500 mL within a 56 day period
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Belimumab

    Reconstituted solution for intravenous infusion

    Drug: Belimumab

  • Placebo comparator
    Normal saline

    Solution for intravenous infusion

    Drug: Normal saline placebo

Interventions

  • 10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)

    Also known as: Benlysta/LymphoStat-B

  • DrugNormal saline placebo

    Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Platelet count

    Change in platelet count

    Time frame: Baseline, week 28

  2. Anti-platelet autoantibodies

    Change in anti-platelet autoantibodies

    Time frame: Baseline, week 28

Secondary outcomes

  1. Platelet count (time)

    Time to first response of platelet count increase \>20,000/microlitre (μl) from baseline

    Time frame: Baseline, week 0, 2, 4, 8, 12, 16, 20, 24, 28

  2. Platelet count (incidence)

    Incidence of response of platelet count increase \>20,000/μL from baseline

    Time frame: Baseline, week 28

  3. Platelet count (incidence of complete response)

    Incidence of complete response as defined by platelet count to \>100,000

    Time frame: Baseline, week 28

  4. Platelet count (incidence of doubling)

    Incidence of subjects with ≥2 times baseline platelet count

    Time frame: Baseline, week 28

  5. Vital signs

    Change in vital signs outside normal range

    Time frame: Baseline, week 0, 2, 4, 8, 12, 16, 20, 24, 28, 40

  6. Clinical chemistry and haematology

    Change in clinical chemistry and haematology

    Time frame: Baseline, week 2, 4, 8, 12, 16, 20, 24, 28, 40

  7. Immunogenicity

    Change in immunogenicity

    Time frame: Baseline, week 12, 28, 40, 52

  8. Serum concentrations of belimumab

    Change in serum concentrations of belimumab

    Time frame: Baseline, week 2, 8, 24, 28, 40, 52

  9. Serum and/or platelet bound anti-platelet antibodies

    Change in serum and/or platelet bound anti-platelet antibodies

    Time frame: Baseline, week 4, 8, 12, 16, 20, 24, 28, 40, 52

  10. B cell and T cell sub-populations and B lymphocyte stimulator (BLyS) receptor

    Change in B cell and T cell sub-populations and BLyS receptor

    Time frame: Baseline, week 4, 8, 16, 24, 40, 52

  11. Antigen-specific B cells and T cells

    Change in antigen-specific B cells and T cells

    Time frame: Baseline, week 8, 16, 24, 40

  12. Serum cytokine/chemokine profile

    Change in serum cytokine/chemokine profile

    Time frame: Baseline, week 8, 16, 24, 28, 40

  13. Transcriptome profile

    Change in transcriptome profile

    Time frame: Baseline, week 8, 28

  14. Autoantibody profile

    Change in autoantibody profile

    Time frame: Baseline, week 28

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2011
First posted
Sep 26, 2011
Start
Mar 2013
Primary completionEst.
Apr 2015
CompletionEst.
Apr 2015
Last update
Jul 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01440361
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 26, 2011
Start date
Mar 2013
Primary completion
Apr 2015 (estimated)
Completion
Apr 2015 (estimated)
Last update
Jul 28, 2014

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion